ODAC to discuss Daiichi Sankyo's pexidartinib, quizartinib NDAs

FDA’s Oncologic Drugs Advisory Committee will meet on May 14 to discuss

Read the full 127 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE